Analyst initiated coverage on Ascentage Pharma
$AAPG
Biotechnology: Pharmaceutical Preparations
Health Care
Analyst initiated coverage of Ascentage Pharma with a rating of Overweight
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/27/2025 | Overweight | Analyst |
6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
S-8 - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
ROCKVILLE, Md. and SUZHOU, China, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management is scheduled to participate in the following investor conferences in November 2025. Goldman Sachs APAC Healthcare Corporate Day 2025: One-on-one and group investor meetings on November 5Stifel 2025 Healthcare Conference: Presentation on November 13 at 2:40 pm EST About Ascenta
ROCKVILLE, Md. and SUZHOU, China, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management will participate in the following investor conferences in October 2025. Piper Sandler Virtual Oncology Symposium: Fireside chat at 10:30 am EDT on October 10J.P. Morgan Global Healthcare Shanghai Conference: One-on-one and group investor meetings on October 16-172025 BofA China
ROCKVILLE, Md. and SUZHOU, China, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management will participate in the following investor conferences in September 2025. Citi's 2025 Biopharma Back to School: Fireside chat at 4:00 pm EDT on September 3Cantor Global Healthcare Conference 2025: Fireside chat at 2:45 pm EDT on September 4H.C. Wainwright 27th Annual Global Inv
Analyst initiated coverage of Ascentage Pharma with a rating of Overweight
ROCKVILLE, Md. and SUZHOU, China, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced today that it will release its six months 2025 unaudited interim results and provide business updates at 7:00 pm Eastern Daylight Time (EDT) on August 20, 2025 / 7:00 am Hong Kong Time (HKT) on August 21, 2025. Analysts and investors are invited to join the investor webcast with Q&A, conducted by the Company's management team. Ascentage Pharma will host a Chinese (Mandarin) language investor webcast at 9:00 pm EDT on Aug
ROCKVILLE, Md. and SUZHOU, China, March 12, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ:AAPG, HKEX: 6855)), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that it will release full year 2024 financial results, and provide an update on recent developments on March 27, 2025 at 7:00 am Eastern Daylight Time (EDT) / 7:00 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by the Ascentage management team. The English conference call and webcast will be he